Login / Signup

Cost-per-remitter with esketamine nasal spray versus standard of care for treatment-resistant depression.

Urvi DesaiNoam Y KirsonAndrea GuglielmoHoa H LeTimothy SpittleJoshua Tseng-ThamMay ShawiJohn J Sheehan
Published in: Journal of comparative effectiveness research (2021)
Aim: Estimate the cost-per-remitter with esketamine nasal spray plus an oral antidepressant (ESK + oral AD) versus oral AD plus nasal placebo (oral AD + PBO) among patients with treatment-resistant depression. Patients & methods: An Excel-based model was developed to estimate the cost-per-remitter for ESK + oral AD versus oral AD + PBO over 52 weeks from multiple US payer perspectives. Clinical end points and cost inputs were derived from clinical trials and the literature, respectively. Results: Under the base-case scenario, the cost-per-remitter for ESK + oral AD and oral AD + PBO were as follows: Commercial: US$85,808 versus US$100,198; Medicaid: US$76,236 versus US$96,067; Veteran's Affairs: US$77,765 versus US$104,519; and Integrated Delivery Network: US$103,924 versus US$142,766. Conclusion: The findings suggest that ESK + oral AD is a cost-efficient alternative treatment for treatment-resistant depression compared with oral AD + PBO.
Keyphrases
  • clinical trial
  • depressive symptoms
  • healthcare
  • newly diagnosed
  • chronic pain
  • sleep quality
  • prognostic factors
  • health insurance
  • gestational age
  • replacement therapy